Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
PI 3-Kinase p110 gamma Antibody (OTI2B1) - Azide and BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP273397
Description
PI 3-Kinase p110 gamma Monoclonal specifically detects PI 3-Kinase p110 gamma in Human, Mouse, Rat samples. It is validated for Western Blot, Immunohistochemistry.Specifications
PI 3-Kinase p110 gamma | |
Monoclonal | |
LYOPH | |
Western Blot 1:1000, Immunohistochemistry 1:150 | |
1-phosphatidylinositol 3-kinase, EC 2.7.1, EC 2.7.1.153, p110-gamma, p120-PI3K, phosphatidylinositol 3 kinase gamma, p110 gamma, phosphatidylinositol 3-kinase catalytic 110-kD gamma, phosphatidylinositol 3-kinase, catalytic, gamma polypeptide, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, phosphoinositide-3-kinase gamma catalytic subunit, phosphoinositide-3-kinase, catalytic, gamma polypeptide, PI3CG, PI3K, PI3Kgamma, PI3K-gamma, PI3-kinase subunit gamma, PIK3, PtdIns-3-kinase subunit gamma, PtdIns-3-kinase subunit p110-gamma | |
Mouse | |
126.3 kDa | |
100 μg | |
Primary | |
Reconstitute with PBS (pH 7.3). To use this carrier-free antibody for conjugation experiments, another round of desalting is highly recommended. | |
Store at -20°C. Avoid freeze-thaw cycles. | |
IgG2a |
Western Blot, Immunohistochemistry | |
OTI2B1 | |
Unconjugated | |
Lyophilized from PBS (pH 7.3) with 8% Trehalose with No Preservative | |
PIK3CG | |
Full length human recombinant protein of human PIK3CG(NP_002640) produced in HEK293T cell. | |
Affinity Purified | |
mTOR Pathway, Phospho Specific, Signal Transduction | |
5294 | |
Human, Mouse, Rat | |
Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction